Personalized CRISPR Remission™ in Autoimmune Disease: A State-Dependent Gene Editing Framework for Durable Immune Reset

A systems-level model integrating timing, immune stability, environmental context, and personalized recovery to improve remission outcomes and reduce long-term disease burden.

This paper is part of the CYNAERA CRISPR Remission™ Library, a comprehensive resource defining how gene editing is applied to autoimmune and infection associated chronic conditions through personalized, state-dependent CRISPR pathways.

By Cynthia Adinig

1. Executive Summary: CRISPR Remission™ and the Future of Autoimmune Gene Editing

Autoimmune disease represents one of the most compelling and structurally under-modeled frontiers for CRISPR-based therapeutic development. While gene editing has historically focused on monogenic disorders and oncology, emerging translational and clinical evidence suggests that immune-mediated diseases may represent one of the clearest pathways to achieving durable, drug-free remission (June et al., 2018; Georgiadis et al., 2022). Recent immune-reset studies, particularly CD19 CAR-T and BCMA-directed approaches, have shifted remission from an aspirational concept toward a measurable clinical outcome in severe refractory disease.

At the same time, the true scale of autoimmune disease remains incompletely measured. Current prevalence estimates are derived primarily from diagnosed populations and therefore capture only the visible portion of disease burden. This leaves out patients in pre-diagnostic states, those with fluctuating or misclassified symptoms, and those whose disease remains structurally under-recognized. Similar dynamics are visible across Long COVID, ME/CFS, dysautonomia, and related immune-volatile conditions, where instability, delayed recovery, and symptom fluctuation challenge diagnosis-bound models of disease (Nalbandian et al., 2021; Komaroff and Bateman, 2021; Lerner et al., 2015). Within the CRISPR Remission™ framework, these dynamics are not treated as noise but as structured signal, captured longitudinally through systems such as SymCas™, which model temporal symptom patterns and reveal early instability.

The economic implications of this gap are substantial. U.S. federal strategic planning documents estimate that autoimmune diseases account for more than $100 billion annually in direct healthcare costs, while the broader societal burden is substantially higher once disability, lost productivity, and caregiver impact are considered. This means autoimmune disease is better understood not as a narrow treatment-cost problem, but as a lifecycle accumulation problem that begins before diagnosis and compounds across time (Lerner et al., 2015; Birnbaum et al., 2010).

This paper builds directly on the CRISPR Remission: A Flare-Aware Gene Editing Pathway Engine for Immune-Volatile Chronic Disease abstract presented at CRISPRMED26, which introduced state-dependent gene editing as a necessary shift for immune-volatile disease. That abstract centered Long COVID and ME/CFS because those conditions make the failures of static intervention models unusually visible: delayed recovery, fluctuating baseline, environmental sensitivity, and non-linear relapse dynamics. The current paper extends that logic into autoimmune disease, positioning autoimmune remission not as a separate concept, but as a central application domain for the broader CRISPR Remission™ architecture. Recent progress in the field reinforces this move. Müller, Schett, and colleagues demonstrated in a 2026 Nature Medicine basket trial that CD19 CAR-T therapy can induce durable drug-free remission across multiple severe autoimmune diseases, including systemic lupus erythematosus, systemic sclerosis, and idiopathic inflammatory myopathy (Müller et al., 2026). Vu and colleagues showed in Nature Medicine that BCMA-directed mRNA CAR-T therapy in generalized myasthenia gravis may offer a more transient, repeatable, and potentially outpatient-compatible route to immune reprogramming (Vu et al., 2026). Together, these studies suggest that autoimmune remission is increasingly being approached as a system-level reset rather than a narrower symptom-management endpoint.

CRISPR Remission™ and CRISPR²™ extend this trajectory by introducing a framework for timing, readiness, stabilization, and recovery in gene editing. Rather than treating intervention as a single molecular event, these models define remission as the outcome of coordinated system-state alignment across immune, environmental, and functional domains. Within this architecture, temporal patterning and early instability are captured through SymCas™, environmental inputs are modeled through systems such as VitalGuard™, readiness is evaluated through the Target Readiness Index™ (TRI), and system instability is actively managed through the STAIR Stable Method™, which provides structured stabilization prior to intervention. CRISPR²™ then aligns deployment and recovery with the resulting system state. This perspective is particularly relevant in autoimmune disease and related immune-volatile conditions, where timing, baseline instability, environmental pressure, and recovery behavior may determine success as much as the intervention itself.

Architecture at a Glance

Within this paper, the CRISPR Remission™ architecture operates across four connected levels:

• Scale: corrected prevalence, Stage Zero™ detection, and diagnostic undercount

• Failure analysis: why current treatment models misread dynamic disease as stable disease

• Deployment logic: CRISPR Remission™, CRISPR²™, TRI, and STAIR as readiness-gated intervention architecture

• System impact: trial design, economic burden, hidden costs, and remission-oriented redesign

Although this paper centers autoimmune disease, its role is intentionally broader. Companion analyses examine disease-specific CRISPR Remission™ pathways in systemic lupus erythematosus, type 1 diabetes, and CRPS, while the conceptual architecture also extends across rheumatoid arthritis, multiple sclerosis, Long COVID, ME/CFS, and dysautonomia-spectrum conditions. In this way, autoimmune disease is positioned not as an isolated category, but as a central hub within a broader class of immune-volatile conditions in which personalization, timing, stability, and environmental context determine therapeutic success.

2. Autoimmune Disease as a CRISPR Remission Frontier

Autoimmune disease represents a convergence point between biological complexity and therapeutic opportunity, positioning it as a leading candidate domain for remission-oriented gene editing. Unlike monogenic disorders defined by a single pathogenic mutation, autoimmune diseases arise from dysregulated immune recognition, chronic inflammation, and multi-factorial interactions between genetic predisposition, environmental exposure, and immune memory (Davidson and Diamond, 2001; Rose and Bona, 1993).

While this complexity has historically limited curative approaches, it also creates a system in which targeted immune reprogramming may yield disproportionate benefit when the correct cell populations, timing windows, and recovery conditions are identified. This shift is now increasingly visible in the autoimmune CAR-T literature. Schett’s group and collaborators have been central to this transition. Early CD19 CAR-T work in refractory systemic lupus erythematosus demonstrated that depletion of autoreactive B-cell populations could induce deep remission. That signal has since expanded. In their 2026 Nature Medicine basket trial, Müller, Schett, and colleagues showed that CD19 CAR-T therapy could induce durable, drug-free remission across multiple severe autoimmune diseases, including lupus, systemic sclerosis, and idiopathic inflammatory myopathies (Müller et al., 2026). This study is particularly important because it reframes autoimmune remission as a cross-condition translational strategy rather than a single-disease phenomenon.

At the same time, the field is rapidly diversifying beyond CD19 depletion. Vu and colleagues’ 2026 Nature Medicine study in generalized myasthenia gravis demonstrated that BCMA-directed mRNA CAR-T therapy may provide a more transient and potentially repeatable form of immune reprogramming (Vu et al., 2026). This suggests that remission may not depend on a single platform, but instead on a family of immune-reset strategies with different durability, safety, and deployment characteristics.

A defining feature of autoimmune disease is its relapsing-remitting behavior. Patients rarely experience stable, continuous disease activity. Instead, symptoms fluctuate over time in response to infection, stress, hormonal shifts, and environmental exposure. These dynamics reflect underlying instability in immune regulation, where the system oscillates between partial control and active disease (Smolen et al., 2023). Importantly, this pattern is not unique to autoimmune disease. Similar relapsing-remitting dynamics are central to Long COVID, ME/CFS, dysautonomia, and other infection-associated chronic conditions.

In our CRISPRMED26 flare-aware abstract, these conditions were used to illustrate how static intervention models fail in systems defined by variability, delayed recovery, and environmental sensitivity. Extending that framework into autoimmune disease is not a shift away from that work. It is a direct continuation of it. Within the broader CYNAERA architecture, these dynamics are made operational through systems such as SymCas™, which captures temporal symptom patterning, and VitalGuard™, which models the environmental conditions that can amplify or suppress system stability.

Traditional therapeutic approaches, including corticosteroids, biologics, and disease-modifying agents, are designed to suppress immune activity rather than restore underlying system stability (Firestein and McInnes, 2017). While these treatments improve outcomes, they are associated with long-term dependence, incomplete response, and variable durability. Many patients cycle through multiple therapies over time, reflecting both disease heterogeneity and limitations in current treatment models (Siegel et al., 2023).

CRISPR Remission™ reframes this landscape by focusing on the conditions under which durable remission becomes possible. In autoimmune disease, remission is not simply the absence of symptoms, but the restoration of immune tolerance and longitudinal system stability (Doria et al., 2005). This perspective aligns with the CYNAERA Remission Standard™, which prioritizes resilience, flare reduction, and sustained functional recovery over single timepoint improvement.

Achieving this outcome requires more than precise gene targeting. It requires understanding when the immune system is most receptive to intervention, how it responds to perturbation, and how stability can be maintained following therapeutic modification. These considerations are formalized in CRISPR²™, which integrates readiness, stabilization, and personalized recovery into a unified deployment architecture. Within that model, readiness is evaluated through TRI, instability is actively managed through the STAIR Stable Method™, and both temporal fluctuation and environmental pressure are incorporated into intervention logic rather than treated as secondary variables.

Most Promising Expansion Lanes in Autoimmune CRISPR Remission™

The current literature suggests that autoimmune CRISPR Remission™ is not a single-path strategy, but a set of expansion lanes with varying levels of readiness, mechanistic clarity, and translational momentum.

Expansion lane	Why it matters now	Key signals
Systemic lupus erythematosus (SLE)	Strongest current remission proof-of-concept	CD19 CAR-T remission work led by Schett and Müller (Nature Medicine, 2026)
Systemic sclerosis (SSc)	High morbidity, now included in remission basket trials	Cross-condition CAR-T remission data (Müller et al., 2026)
Idiopathic inflammatory myopathies (IIM)	Expands remission beyond single-disease models	Included in multi-condition immune-reset architecture
Generalized myasthenia gravis (gMG)	Demonstrates platform diversification	BCMA-directed mRNA CAR-T (Vu et al., 2026, Nature Medicine)
Rheumatoid arthritis (RA)	High prevalence and major economic burden	Promising but requires more refined targeting and timing (Smolen et al., 2023)
Multiple sclerosis (MS)	Strong conceptual fit for immune reset and tolerance models	Increasing discussion of immune reprogramming strategies (Compston and Coles, 2008)
Sjögren’s / overlap CTD	Likely under-recognized burden, mechanistic overlap	Expanding rheumatic disease frameworks (Ramos-Casals et al., 2012)

These expansion lanes are not equivalent in readiness. Some, such as lupus and related rheumatic diseases, already demonstrate strong immune-reset feasibility. Others, such as rheumatoid arthritis and multiple sclerosis, may require more advanced timing, stratification, and stabilization logic. This distinction reinforces the importance of CRISPR²™, which explicitly accounts for intervention timing, system readiness, and recovery dynamics.

Why Autoimmune Disease Functions as the Hub

Autoimmune disease is strategically important because it does three things at once:

• provides the clearest near-term translational evidence for remission-oriented immune reset

• exposes the limitations of static, diagnosis-bound treatment models

• creates a bridge into related immune-volatile conditions such as Long COVID, ME/CFS, and dysautonomia

Taken together, these developments suggest that autoimmune disease is not only a viable target for CRISPR-based remission, but a central node within a broader ecosystem of immune-volatile conditions. In that sense, autoimmune disease functions as both a proving ground and a bridge: a domain where remission logic is first validated in clinical settings and a platform from which that logic can extend across the broader CRISPR Remission™ architecture.

3. Population Scale, Diagnostic Blind Spots, and Corrected Autoimmune Prevalence

Autoimmune disease is widely recognized as a major contributor to chronic illness burden, yet its true scale remains incompletely measured. Current prevalence estimates primarily reflect the portion of disease that is formally diagnosed, coded, and captured within healthcare systems. As a result, these figures function more as measures of clinical visibility than as comprehensive representations of population burden (Cooper et al., 2009; Hayter and Cook, 2012).

Across conditions, prevalence estimates vary widely but consistently demonstrate substantial impact. Systemic lupus erythematosus affects an estimated 200,000 individuals in the United States, multiple sclerosis approaches 1 million cases, and autoimmune thyroid disease affects tens of millions globally (Jacobson et al., 1997; Lerner et al., 2015). However, these figures are constrained by reliance on confirmed diagnosis, which introduces systematic underestimation in conditions characterized by delayed recognition, fluctuating symptoms, and evolving classification criteria.

Diagnostic delay is a well-documented feature of autoimmune disease. Patients frequently experience prolonged periods of symptoms prior to diagnosis, often spanning months or years, particularly in conditions such as Sjögren’s syndrome, lupus, and inflammatory arthritis (Hayter and Cook, 2012; Ramos-Casals et al., 2012). This delay reflects both biological complexity and structural limitations within healthcare systems, including fragmented care pathways, symptom overlap across specialties, and inconsistent application of diagnostic criteria.

As outlined in Stage Zero™: When the Immune System Is Active Before It Is Named, immune-mediated disease frequently begins prior to formal diagnosis, during a phase of structured but unclassified instability. This concept aligns with broader research demonstrating that autoimmune conditions often evolve gradually, with early symptoms that are clinically meaningful but insufficiently specific to meet classification thresholds (Rose and Bona, 1993; Davidson and Diamond, 2001). During this period, patients may experience multi-system dysfunction, fluctuating symptom patterns, and functional impairment despite normal or inconclusive laboratory findings.

This early-phase invisibility is compounded by diagnostic friction embedded within real-world care systems. The CYNAERA Diagnostic Multiplier™ reflects the impact of these factors by recognizing that prevalence is shaped not only by disease incidence, but by the probability of clinical recognition. Seronegativity, symptom variability, limited access to specialty care, and provider bias all contribute to suppressed visibility across autoimmune disease. These dynamics are consistent with literature demonstrating underdiagnosis and misclassification in conditions with heterogeneous presentation and overlapping symptom profiles (Smolen et al., 2023; Firestein and McInnes, 2017).

To address these limitations, CYNAERA’s US-CCUC™ applies structured correction to diagnosis-based prevalence by accounting for delayed diagnosis, relapsing-remitting disease behavior, and cross-condition overlap. This approach reflects a broader recognition within epidemiology that chronic disease burden is frequently underestimated when measurement relies on static classification rather than longitudinal disease behavior (Lerner et al., 2015). When viewed through this combined lens, autoimmune disease does not exist as a single visible population, but as a layered system of detection, recognition, and classification.

Autoimmune Disease Visibility and Prevalence Layers

Layer	Description	Visibility in Current Systems	Key Limitation
Diagnosed Autoimmune Disease	Confirmed cases meeting clinical and diagnostic criteria	High	Represents only the visible portion of disease burden
Undiagnosed but Clinically Active Disease	Persistent symptoms and functional impairment without formal diagnosis	Moderate to Low	Fragmented care, symptom dismissal, delayed specialist access
Stage Zero™ Autoimmune Disease	Pre-diagnostic immune instability with structured symptom patterns	Very Low	Not captured by current diagnostic frameworks
Overlapping / Evolving Conditions	Patients transitioning or presenting across multiple disease categories	Low	Misclassification and specialty silos

This layered structure reveals that a significant portion of autoimmune disease exists outside formal recognition. The result is a systematic underestimation of true disease burden, with entire populations excluded from both prevalence estimates and treatment frameworks.

Corrected Autoimmune Prevalence Framework (US-CCUC™ + DM™)

What it is A structured method to estimate true autoimmune disease burden by correcting diagnosis-based prevalence for undercount and diagnostic suppression.

How it works The model applies two key adjustments:

• Undercount Correction (US-CCUC™) to account for Stage Zero™ plus undiagnosed populations

• Diagnostic Multiplier™ (DM™) to adjust for real-world diagnostic friction

Formula:  Corrected Prevalence = Baseline × (1 + Undercount Rate) × Diagnostic Multiplier

Selected Autoimmune Conditions: Reported vs Corrected Prevalence (U.S.)

Condition	Reported Prevalence	Adjusted Range (US-CCUC™ + DM™)	Key Drivers of Undercount
Systemic Lupus Erythematosus (SLE)	~200,000	300,000 to 500,000	Diagnostic delay, seronegativity, symptom variability
Myasthenia Gravis (MG)	~60,000	90,000 to 150,000	Fluctuating symptoms, misdiagnosis
Psoriatic Arthritis (PsA)	~1M	1.5M to 2.5M	Dermatology/rheumatology fragmentation
Ankylosing Spondylitis (AS)	~1M	1.5M to 2M	Imaging delays, gender bias
Hashimoto’s Thyroiditis	~14M	18M to 24M	Subclinical disease, endocrine overlap
Sjögren’s Syndrome	~4M	6M to 10M	Under-recognition, diffuse symptoms
Multiple Sclerosis (MS)	~1M	1.3M to 1.8M	Early-stage invisibility
Autoimmune Hemolytic Anemia (AIHA)	~30,000	50,000 to 100,000	Rare disease misclassification

Across conditions, undercount follows predictable patterns. Diseases characterized by fluctuating symptoms, multi-system involvement, or fragmented care pathways show the largest expansion beyond reported prevalence (Ramos-Casals et al., 2012; Gladman et al., 2005; Compston and Coles, 2008). The majority of autoimmune disease likely exists outside of formal diagnosis at any given time.

Worked Example: U.S. Autoimmune Population

Scenario	Baseline	Undercount	DM™	Corrected Population
Reported	20M	—	—	20M
Conservative	20M	30%	1.20	31.2M
Moderate	20M	50%	1.40	42M
High-Range	20M	75%	1.60	56M

Interpretation

• Reported prevalence reflects only diagnosed cases

• Corrected models include Stage Zero™ populations

• Corrected models include undiagnosed active disease

• Corrected models include diagnostic suppression

• Even conservative adjustment suggests millions of additional patients are excluded from current models

This reframing has direct implications for therapeutic development. Clinical trials and intervention strategies built around diagnosed populations inherently exclude a substantial portion of affected individuals. In immune-volatile and relapsing conditions, where disease expression evolves over time, this exclusion is structural rather than incidental. CRISPR²™ addresses this limitation by integrating population-scale understanding with system-state modeling. By incorporating Stage Zero™ detection, Diagnostic Multiplier™ dynamics, and corrected prevalence logic into intervention design, the framework aligns therapeutic strategy with the full spectrum of disease rather than its most visible subset. Understanding autoimmune prevalence in this way is not simply an epidemiologic refinement. It is a prerequisite for designing remission-oriented therapies that reflect how disease develops, persists, and becomes visible within real-world systems.

4. Why Current Autoimmune Treatment Models Fall Short: A Structural Mismatch

Despite significant advances in immunology and biologic therapeutics, current autoimmune treatment models remain fundamentally limited in their ability to achieve durable remission. This limitation is often framed as a therapeutic gap. In practice, it reflects a deeper structural mismatch between how autoimmune disease is defined, measured, and treated. Most existing therapies are designed to suppress immune activity rather than restore immune tolerance, resulting in partial disease control rather than system-level resolution (Firestein and McInnes, 2017; Smolen et al., 2023). Corticosteroids, conventional disease-modifying antirheumatic drugs, and biologic agents such as TNF inhibitors and B-cell-targeting therapies have improved outcomes across multiple autoimmune diseases. However, these approaches are typically associated with long-term treatment dependence, incomplete response, and variable durability.

Many patients cycle through multiple therapies over the course of their disease, reflecting both heterogeneity in disease mechanisms and structural limitations in current treatment paradigms (Siegel et al., 2023). The central issue is not simply that treatments are imperfect. It is that they are applied within a model that treats autoimmune disease as a stable, diagnosis-bound condition rather than a dynamic system.

4.1 Static Treatment Models in Dynamic Disease Systems

Autoimmune diseases are characterized by fluctuating immune activity, delayed physiologic response, and sensitivity to both internal and external triggers. Disease expression changes over time based on immune activation, environmental exposure, autonomic state, and recovery conditions. Despite this, treatment decisions are often based on isolated clinical snapshots, including laboratory values, symptom reports, and single-visit assessments. This creates a structural mismatch in which static interventions are applied to dynamic systems. The result is predictable. Early destabilization phases are often missed or under-treated. Recovery phases may be over-treated or misinterpreted. Relapse is treated as failure rather than expected system behavior.

A major reason this happens is that conventional models are poorly equipped to track temporal patterning. In immune-volatile disease, symptom burden often unfolds through sequences, lagged responses, and recurrent flare architecture rather than single-event deterioration. Within the CYNAERA framework, this is the problem SymCas™ was designed to solve. By modeling symptom sequencing, persistence, and delayed response patterns over time, SymCas™ captures the very dynamics that static assessment misses. Without that type of temporal structure, clinically meaningful fluctuation is repeatedly mistaken for inconsistency rather than recognized as patterned biological behavior.

A second and equally critical gap is the absence of structured stabilization prior to intervention. In current models, treatment is typically initiated once disease activity crosses a clinical threshold, without regard for whether the system is in a state capable of supporting durable response. This results in intervention being applied during periods of high volatility, where inflammatory load, autonomic instability, or environmental pressure may reduce effectiveness and increase variability. Within the CRISPR Remission™ framework, this gap is addressed through the STAIR Stable Method™, which introduces a structured stabilization phase designed to reduce system volatility and improve readiness prior to intervention. Without such a stabilization layer, treatment timing remains reactive, and outcomes remain inconsistent even when the underlying therapeutic mechanism is sound.

This mismatch is not unique to autoimmune disease. It has been extensively documented in infection-associated chronic conditions, including Long COVID, ME/CFS, POTS, and related post-infectious states, where symptom variability and delayed response patterns consistently lead to mis-timed intervention and inconsistent care (Davis et al., 2023; Putrino et al., 2023). Across these conditions, the failure is not only therapeutic. It is architectural.

4.2 Failure to Model Disease as Terrain Rather Than Label

A second limitation of current autoimmune models is their reliance on disease labels rather than underlying system behavior. As outlined in the IACC Terrain framework, conditions such as Long COVID, ME/CFS, dysautonomia, mast-cell disorders, and autoimmune disease frequently share overlapping downstream mechanisms, including immune dysregulation, autonomic instability, mitochondrial dysfunction, and inflammatory signaling. Treating these conditions as isolated silos obscures shared biology and reinforces fragmented care.

This fragmentation produces several downstream problems. Patients with overlapping mechanisms are treated as separate cases. Therapies are evaluated within narrow diagnostic categories rather than shared biology. Clinical trials average across heterogeneous populations, diluting meaningful signal. In autoimmune disease, this leads to treatment strategies that target surface manifestations rather than underlying system dynamics. In IACC populations, the same issue results in repeated trial failure, where heterogeneous cohorts obscure treatment effects that may be significant within specific mechanistic subgroups (Davis et al., 2023; Putrino et al., 2023). The issue is not lack of data. It is failure to organize data around the correct model.

4.3 Persistence of Immune Memory and Incomplete Reset

Even when current therapies successfully reduce disease activity, they rarely eliminate the underlying drivers of immune dysregulation. Autoreactive immune populations, dysfunctional signaling pathways, and maladaptive immune memory often persist beneath clinical suppression. As a result, disease frequently reactivates when therapy is reduced or discontinued, particularly in systemic autoimmune diseases such as lupus and rheumatoid arthritis (van Vollenhoven, 2011; Doria et al., 2005).

This dynamic is consistent with broader observations across immune-volatile conditions, where systems may appear stable under controlled conditions but remain vulnerable to relapse when exposed to stress, infection, or environmental triggers. Current models interpret this as treatment limitation. In reality, it reflects incomplete system reset.

4.4 Environmental and Recovery Context as Missing Variables

Another major limitation of current treatment models is the failure to incorporate environmental and recovery context into disease management. Environmental exposures, including air quality, damp housing, toxicants, and climate-related stressors, have been shown to influence inflammatory burden, autonomic stability, and disease activity across multiple conditions (Baxter et al., 2021; Brewer et al., 2013). These factors are particularly relevant in structurally exposed populations, where environmental load contributes to both disease severity and health access gaps.

Despite this, environmental variables are rarely incorporated into treatment planning or trial design. Instead, they are treated as confounders or noise, rather than as active drivers of system behavior. Within the CYNAERA framework, this is precisely where VitalGuard™ becomes necessary. VitalGuard™ models environmental conditions such as particulate exposure, humidity, mold burden, and atmospheric volatility as continuous modifiers of system stability and flare risk. In other words, it treats environment not as an afterthought, but as an operational input that alters readiness, treatment response, and recovery durability.

Within the IACC framework, environment is therefore modeled as a co-intervention rather than a background variable, reflecting its role in shaping both baseline stability and response to treatment. When this layer is missing, variability in treatment response becomes harder to interpret, trial outcomes become noisier, and therapeutic efficacy is more easily misclassified.

4.5 Implications for Remission-Oriented Care

Taken together, these limitations reveal that current autoimmune treatment models are not simply incomplete. They are structurally misaligned with the biology they are intended to treat. Autoimmune disease is dynamic rather than static. It is system-driven rather than label-bound. It is influenced by environment and recovery context. It is characterized by persistent immune memory and by temporal patterns of instability that cannot be adequately captured through snapshot-based care.

Yet current models apply static interventions, rely on diagnosis-based classification, ignore environmental and longitudinal dynamics, and measure outcomes using isolated assessments. This mismatch explains why durable remission remains rare despite therapeutic advances.

As emphasized in the CYNAERA Remission Standard™, meaningful remission requires sustained system stability, resilience to perturbation, reduced dependence on continuous intervention, and alignment between treatment and system state. Addressing this gap requires more than incremental improvement in therapeutics. It requires a shift in how autoimmune disease is conceptualized. CRISPR Remission™ and CRISPR²™ respond to this need by reframing intervention as a state-dependent, system-level process rather than a static treatment event.

5. CRISPR Remission™ and CRISPR²™: A State-Dependent System Architecture

CRISPR Remission™ reframes gene editing in autoimmune disease from a problem of molecular targeting to a problem of system alignment. Conventional approaches assume that once a biologically relevant target is identified, intervention can proceed with predictable outcomes. In immune-volatile disease, this assumption breaks down. Intervention success depends not only on what is targeted, but on whether the biological system is capable of supporting that intervention at the moment it is delivered. This principle was first outlined in our CRISPRMED26 CRISPR Remission: A Flare-Aware Gene Editing Pathway Engine for Immune-Volatile Chronic Disease"abstract, where conditions such as Long COVID and ME/CFS made the failure of static intervention models particularly visible. In those systems, delayed recovery, fluctuating baselines, and environmental sensitivity revealed that timing and system state are not secondary considerations, but primary determinants of outcome. Autoimmune disease extends that insight into a domain where immune-reset strategies have already demonstrated clinical feasibility.

The limitations outlined in prevalence modeling, treatment mismatch, and hidden cost accumulation are not independent failures. They are manifestations of the same underlying issue: intervention is not aligned with system state. CRISPR Remission™ and CRISPR²™ address this by introducing a unified architecture in which detection, stratification, readiness, stabilization, and deployment operate as a coordinated system rather than isolated steps.

CRISPR²™ formalizes this shift into a structured deployment architecture. Defined as CRISPR Readiness Index, Stabilization, and Personalized Recovery, it transforms gene editing from a discrete event into a coordinated, state-dependent process. At the center of this architecture is the Target Readiness Index™ (TRI), which serves as the decision layer for intervention. TRI reframes target selection by asking not whether a gene is relevant, but whether it is deployable within a given system state. This distinction reflects broader challenges in translational medicine, where variability in immune activation, environmental exposure, and physiologic stability contributes to inconsistent outcomes even when targets are well-defined (Topol, 2019; Smolen et al., 2023).

Rather than functioning as a binary eligibility threshold, TRI captures readiness as a dynamic condition that shifts over time. A target may be appropriate in one system state and inappropriate in another, depending on factors such as inflammatory burden, autonomic stability, environmental load, and recovery capacity. Temporal patterning captured through systems such as SymCas™ allows these shifts to be detected earlier, while environmental modeling through systems such as VitalGuard™ ensures that external pressures are incorporated into readiness assessment rather than treated as background variability. In this way, readiness becomes something that can be measured, modified, and optimized rather than assumed.

To make this operational, TRI can be understood through its core domains:

Target Readiness Index™ Domains

TRI Domain	What it Captures
Intervention precedent	Strength of existing clinical or translational evidence
Target complexity	Risk, accessibility, and interaction burden
Phenotype clarity	Signal coherence and diagnostic confidence
Timing sensitivity	Volatility and state-dependence of response
System interaction load	Cross-system effects including immune, autonomic, metabolic, and environmental

Stabilization follows directly from TRI. If readiness is insufficient, intervention is not advanced. Instead, the system enters a structured stabilization phase through the STAIR Stable Method™, which is designed to reduce volatility, improve baseline control, and prepare the biological system for durable response. In autoimmune disease, instability is rarely driven by a single variable. Environmental exposures such as air pollution, mold, and climate variability can amplify inflammatory signaling and alter autonomic regulation, directly affecting system behavior (Parks et al., 2017; Brewer et al., 2013; D’Amato et al., 2015). These factors are not peripheral. They actively influence whether an intervention is likely to succeed.

Personalized recovery completes the architecture by extending the same logic beyond intervention. Systems do not remain static after modification. They continue to respond to internal and external stressors. Monitoring recovery, maintaining stability, and adapting to environmental changes are therefore essential to ensuring that initial therapeutic gains translate into durable remission. This phase is inherently dynamic, requiring ongoing integration of temporal patterning, environmental context, and system feedback.

Taken together, CRISPR Remission™ and CRISPR²™ redefine intervention as a coordinated process in which stratification defines the system, SymCas™ captures temporal dynamics, VitalGuard™ quantifies environmental pressure, TRI defines readiness, STAIR enables stabilization, and deployment is conditioned on alignment between all of these layers. Within this model, failure is no longer interpreted solely as a limitation of the target itself. It may instead reflect a mismatch between intervention and system state.

6. Condition Stratification in Autoimmune Disease: A Systems-Based Approach

A central limitation of current autoimmune care is not simply that diseases are treated as homogeneous. It is that stratification occurs only after pattern recognition has already failed. By the time a diagnosis is assigned, disease has often progressed through years of fragmented signals, inconsistent interpretation, and delayed escalation. This is not because the system lacks data. It is because it lacks a framework for assembling that data into a coherent structure early enough to influence trajectory. Pattern-based models such as CDF demonstrate that disease signals are rarely absent. They are distributed. Symptoms appear across specialties, evolve over time, and fluctuate in intensity, creating a pattern that is visible longitudinally but obscured at any single point of care. When these signals are not assembled, stratification defaults to diagnosis-based grouping, which occurs late and often underrepresents the true complexity of the system (Ramos-Casals et al., 2012; Castori et al., 2017; Smolen et al., 2023).

CRISPR Remission™ addresses this by shifting stratification upstream, from diagnosis to pattern coherence. Instead of asking whether a patient meets criteria for a defined condition, the system evaluates how signals accumulate and interact across time. This includes not only symptom clustering and inflammatory activity, but also the rhythm of relapse, the persistence of dysfunction, and the degree to which the system fails to return to baseline after stress. These features are operationalized within CYNAERA through SymCas™, which models symptom sequencing and temporal patterning to identify emerging instability and predict flare trajectories. By capturing how symptoms evolve rather than how they present at a single point, SymCas™ enables earlier and more accurate pattern recognition in immune-volatile disease, where fluctuation is a defining characteristic rather than noise.

Stratification becomes more precise when additional layers are integrated. Disease expression is shaped by trigger context, dominant biological mechanisms, system stability, environmental exposure, and recovery capacity. These variables interact continuously. A patient with an infectious trigger and high autonomic involvement may behave very differently from a patient with a primarily autoimmune-driven pattern, even if both ultimately receive the same diagnosis. Similarly, environmental load can amplify or suppress disease expression, altering both severity and treatment response. Within CYNAERA, this layer is captured through VitalGuard™, which models environmental inputs such as air quality, humidity, particulate exposure, and mold risk to quantify their impact on system stability and flare probability. This allows environmental pressure to be treated as a measurable component of disease state rather than an external confounder, aligning with broader evidence that environmental exposures directly influence immune activation and disease activity (Parks et al., 2017; D’Amato et al., 2015).

This multi-layer structure is not theoretical. It directly determines how intervention should be approached. To make this operational, stratification within the CRISPR Remission™ framework can be understood as a structured synthesis of key system inputs:

Multi-Layer Stratification Framework in CRISPR Remission™

Stratification Layer	What It Defines	Why It Matters for Intervention
Trigger (PCT)	Origin of system disruption	Determines trajectory and relapse risk
Mechanism (Branch Dominance)	Primary biological drivers	Guides targeting strategy
Pattern (CDF + SymCas™)	Signal coherence over time and symptom sequencing	Enables early identification and flare prediction
System State	Stability vs volatility	Determines readiness
Environment (VitalGuard™)	External system pressure	Modulates inflammation, stability, and response
Recovery Context	Resilience and rebound capacity	Determines durability

What distinguishes this model from traditional stratification is not the number of variables, but how they are used. These layers are not descriptive endpoints. They are inputs into TRI. Stratification, in this context, does not answer whether a disease is present. It defines the structure of the system so that readiness can be evaluated. Pattern coherence, temporal dynamics captured through SymCas™, environmental modulation quantified through VitalGuard™, and system stability are translated into TRI scoring, which determines whether specific targets are deployable. This is the point at which stratification becomes operational. It is no longer a classification exercise. It is a prerequisite for decision-making, consistent with emerging precision medicine models that emphasize dynamic, patient-specific system behavior (Topol, 2019; Ashley, 2016).

The consequences of failing to stratify at this level are measurable. Delayed recognition allows disease processes to become more entrenched, increasing treatment resistance and narrowing intervention windows. Patients progress from modifiable instability to chronic dysfunction, often requiring more aggressive and less effective interventions. These patterns are reflected in increased healthcare utilization, higher disability burden, and long-term economic cost (Lerner et al., 2015; Eaton et al., 2020). In this way, stratification is not simply about understanding disease. It is about preserving opportunity. It determines whether intervention occurs when the system is still capable of responding, or after it has already shifted into a more rigid and less reversible state.

7. Measurement and Trial Design for State-Dependent CRISPR in Autoimmune Disease

If autoimmune disease is dynamic, then measurement must reflect that reality. Traditional clinical models rely heavily on single-point laboratory values, episodic symptom reporting, and cross-sectional assessment. While these tools provide useful snapshots, they fail to capture the temporal variability, delayed response, and state-dependent behavior that define immune-mediated disease (Smolen et al., 2023). In this context, measurement does not fail because it lacks data. It fails because it lacks structure across time. This limitation becomes particularly significant in remission-oriented therapies. When outcomes are evaluated without reference to system state, variability in response is often interpreted as inconsistency in the intervention itself. In reality, it may reflect differences in timing, readiness, or external pressure on the system at the moment of deployment. This is especially relevant in gene editing, where intervention durability depends not only on the correctness of the target, but on whether the biological system is capable of supporting stable modification.

Within the CRISPR Remission™ framework, this gap is addressed by shifting measurement from static observation to longitudinal system tracking. Temporal patterning is operationalized through SymCas™, which models symptom sequencing, persistence, and pattern recurrence over time. Rather than treating variability as noise, SymCas™ treats it as signal, allowing early instability to be identified before it escalates into clinically obvious disease states. This enables measurement to capture trajectory rather than isolated events, aligning with the underlying behavior of immune-volatile systems.

This measurement gap is one of the reasons initiatives such as The Eve Research Project matter within the broader CYNAERA ecosystem. By capturing longitudinal, real-world data on symptom fluctuation, environmental exposure, and recovery dynamics in underrepresented populations, The Eve Research Project helps build the kind of structured temporal dataset required for state-dependent modeling in immune-volatile disease.

The Target Readiness Index™ (TRI) builds on this by introducing readiness into both measurement and trial design. Rather than treating participants as interchangeable within a diagnostic category, TRI allows cohorts to be defined based on whether specific targets are deployable within their current system state. This shifts measurement from static observation to state-aware interpretation and aligns with broader concerns in autoimmune research, where heterogeneity has long been recognized as a barrier to reproducibility and signal detection (Komaroff and Bateman, 2021; Smolen et al., 2023). The implications of this shift are most visible in cohort construction. Traditional trials group patients based on diagnosis, assuming a level of biological similarity that often does not exist in practice. Even subtype-based approaches only partially address this issue, as they rarely account for system stability, timing sensitivity, or environmental influence. A readiness-based model introduces an additional layer of control by aligning intervention with system state.

Diagnosis-Based vs TRI-Based Cohort Design

Model	Basis of Grouping	Key Limitation
Diagnosis-based	Shared label	High variability in system state
Subtype-based	Partial mechanistic grouping	Incomplete control of timing and volatility
TRI-based	Target deployability within system state	Reduced noise, improved signal clarity

This reframing also changes how outcomes are interpreted. A lack of response is no longer assumed to indicate target failure. It may instead reflect misalignment between intervention and system state. This distinction is critical in autoimmune and immune-volatile conditions, where timing and stability can determine whether an otherwise effective intervention produces durable benefit.

A major and often under-integrated contributor to this variability is environmental exposure. While autoimmune disease is frequently modeled as internally driven, a substantial body of research demonstrates that environmental factors significantly influence inflammatory signaling, vascular function, and disease activity across multiple autoimmune conditions (Parks et al., 2017; Bernatsky et al., 2011; D’Amato et al., 2015). Within the CRISPR Remission™ framework, these factors are not treated as background noise. They are treated as part of the system state itself. This distinction is essential because environmental load directly affects readiness. A target that appears deployable under stable conditions may become inappropriate when the system is under pressure from particulate exposure, chronic dampness, infectious triggers, or temperature-driven stress.

This layer is operationalized through VitalGuard™, which models environmental conditions such as air quality, humidity, particulate matter, and mold exposure to quantify their impact on system stability and flare risk. By linking environmental data to predicted changes in physiological state, VitalGuard™ allows environmental pressure to be incorporated directly into TRI scoring rather than treated as an uncontrolled external variable. This transforms environmental exposure from a confounder into a measurable component of readiness.

Importantly, these effects are not uniform across autoimmune disease. Different conditions exhibit distinct sensitivity profiles based on their underlying pathophysiology. Particulate air pollution has been strongly associated with increased disease activity in systemic lupus erythematosus and rheumatoid arthritis, likely through amplification of inflammatory and endothelial pathways (Parks et al., 2017; Bernatsky et al., 2011). In contrast, vascular-driven conditions such as systemic sclerosis may be more sensitive to environmental stressors that affect microvascular integrity and tissue perfusion. Endocrine autoimmune conditions, including Hashimoto’s thyroiditis, may be influenced by iodine exposure and endocrine disruptors that alter baseline immune signaling (Burek and Talor, 2009). Gastrointestinal autoimmune conditions such as inflammatory bowel disease are shaped by microbial and dietary environments that directly influence mucosal immunity (Ananthakrishnan, 2015). These distinctions reinforce the need for condition-specific environmental mapping rather than generalized exposure models.

Failure to account for these variables introduces systematic bias into both clinical care and research. Variability in outcomes may be incorrectly attributed to intervention failure when it instead reflects changes in system state driven by environmental exposure. This issue has been widely recognized in clinical research, where uncontrolled heterogeneity and unmeasured external variables reduce reproducibility and obscure true treatment effects (Ioannidis, 2005; Kent et al., 2010). Incorporating environmental context into trial design therefore improves both cohort stability and interpretability of results. In practice, this may include tracking exposure variables such as air quality, humidity, microbial burden, and temperature variability alongside clinical and biomarker data.

Within the CRISPR Remission™ framework, measurement, stratification, and deployment form a continuous system rather than separate stages. Measurement captures how the system behaves over time through longitudinal patterning and symptom sequencing. Stratification organizes that behavior into a coherent structure. TRI evaluates whether intervention is appropriate within that structure by integrating system stability, environmental load, and temporal dynamics. CRISPR²™ then aligns deployment with the resulting state. This progression replaces static evaluation with system-aware decision-making, allowing outcomes to be interpreted in context and distinguishing between therapeutic failure, suboptimal timing, and instability-driven variability. In immune-volatile disease, where fluctuation is intrinsic rather than incidental, this shift is not an optimization. It is a requirement for achieving consistent and durable remission, aligning with broader calls in precision medicine and systems biology to move beyond static, reductionist models toward dynamic, context-aware intervention frameworks (Hood and Flores, 2012; Topol, 2019).

8. Safety Monitoring and State-Dependent Risk Management

Safety monitoring in gene editing has traditionally focused on detecting adverse events after intervention. Standard frameworks emphasize off-target effects, immunogenicity, toxicity, and long-term persistence, with patients monitored intensively during early phases of treatment and followed for extended periods, often exceeding a decade in CRISPR-based therapies (Chehelgerdi et al., 2024; FDA, 2024). These approaches are essential, but they operate within a fundamentally reactive model in which safety is assessed after exposure rather than controlled through deployment conditions.

Within the CRISPR Remission™ and CRISPR²™ architecture, safety is reframed as a function of system state at the time of intervention. Rather than relying solely on post-intervention monitoring, this model introduces state-dependent risk management, in which intervention is conditioned on readiness, stability, and environmental context. This distinction is critical in immune-volatile disease. Variability in outcomes is not always driven by the intervention itself, but by the conditions under which it is delivered. High inflammatory burden, autonomic instability, or environmental stress may increase the likelihood of adverse events or reduce the durability of response, even when the underlying target is biologically appropriate.

Within this framework, safety is operationalized across four integrated layers:

• Pre-intervention readiness (TRI):

  Determines whether a target is deployable within the current system state, reducing the risk of applying intervention during periods of high instability.

  
  

• Stabilization (STAIR Stable Method™):

  Introduces a structured pre-intervention phase designed to reduce volatility, lower inflammatory load, and improve physiologic conditions prior to deployment.

  
  

• Temporal monitoring (SymCas™):

  Captures symptom sequencing and early instability patterns, allowing emerging adverse trajectories to be identified before they reach clinically severe thresholds.

  
  

• Environmental risk modeling (VitalGuard™):

  Quantifies external pressures such as air quality, humidity, and exposure burden, which may modulate immune response and influence both safety and treatment durability.

Together, these layers shift safety from a retrospective assessment to a proactive control system. Intervention is not only evaluated for molecular precision, but for its alignment with system readiness, stability, and environmental context. Post-intervention monitoring remains essential.

Patients undergoing CRISPR-based therapies continue to require longitudinal follow-up to assess durability, delayed adverse effects, and long-term system behavior, consistent with current regulatory guidance. However, within the CRISPR Remission™ framework, these downstream safety measures are complemented by upstream controls that reduce the likelihood of adverse outcomes before intervention occurs. In this sense, safety is no longer defined solely by the absence of complications. It is defined by the alignment between intervention and system state. This represents a shift from monitoring risk to managing it at the point of decision.

9. Economic Impact and System-Level Value in Autoimmune Disease

The economic burden of autoimmune disease reflects not only disease severity, but the consequences of delayed recognition, incomplete stabilization, and treatment models that manage instability rather than resolve it. As established earlier in this paper, conventional prevalence estimates capture only the visible portion of autoimmune burden, while CYNAERA’s correction frameworks suggest a substantially larger population affected by pre-diagnostic dysfunction, fluctuating disease, and structurally suppressed recognition. This distinction matters because economic impact scales directly with prevalence. When autoimmune disease is modeled at corrected burden rather than diagnosed burden alone, its cost profile shifts from a large chronic disease category to a long-horizon systems constraint (Birnbaum et al., 2010; Hayter and Cook, 2012).

Direct Economic Impact: Treatment Inefficiency and Recurrent Clinical Cost

Autoimmune care is currently characterized by recurring specialist visits, repeated diagnostics, long-term biologic or immunosuppressive therapy, flare-related escalation, and inconsistent long-term durability. A significant portion of this cost is driven not only by disease complexity, but by the absence of frameworks that align intervention with biological state. In conventional management, instability is often treated after it becomes clinically obvious rather than when it first becomes actionable. This pattern of reactive care and treatment cycling is well documented across autoimmune conditions, particularly in diseases such as rheumatoid arthritis and lupus, where patients frequently require multiple lines of therapy over time (Smolen et al., 2023; Cross et al., 2014). Using the ranges already modeled across CYNAERA’s economic framework, moderate-to-severe autoimmune disease commonly produces:

Estimated excess direct-care burden:$15,000–$40,000 per patient per year (Birnbaum et al., 2010; Kawatkar et al., 2012)

Within a CRISPR²™ model, the relevant economic question is not whether advanced intervention has a higher headline price, but whether readiness-aligned deployment reduces the instability-driven waste that surrounds treatment. Applying state-aligned intervention efficiency gains to direct care burden produces the following modeled savings:

• 20% efficiency gain → $3,000–$8,000 per patient per year

• 30% efficiency gain → $4,500–$12,000

• 40% efficiency gain → $6,000–$16,000

These gains reflect reduced diagnostic redundancy, fewer ineffective or mistimed interventions, lower flare-related escalation, and improved durability when care is aligned with readiness, stabilization, and recovery rather than administered reactively. Similar cost inefficiencies associated with delayed optimization and treatment switching have been observed across chronic autoimmune cohorts (Sokka et al., 2008; Michaud et al., 2015).

Indirect Economic Impact: Workforce Loss, Disability, and Functional Decline

The indirect burden of autoimmune disease is often even larger than direct medical spend. Patients frequently experience intermittent work loss, reduced work capacity, episodic disability, educational disruption, caregiving dependence, and long-term functional drag. These costs accumulate even in patients who remain formally employed, because productivity, consistency, and advancement are often reduced long before total disability is recognized. Across CYNAERA’s modeled burden architecture, the indirect cost range for moderate-to-severe autoimmune disease commonly falls within:

Estimated indirect burden: $20,000–$80,000 per patient per year

Applying partial recovery or improved functional stability through remission-oriented care yields meaningful modeled economic return:

• 10% improvement → $2,000–$8,000 per patient per year

• 20% improvement → $4,000–$16,000

• 30% improvement → $6,000–$24,000

These gains reflect increased workforce participation, reduced disability dependence, improved educational and occupational continuity, and lower household caregiving strain. They do not require full cure. They reflect partial stabilization and improved system control.

Intervention-Level Cost Logic: Why CRISPR²™ Changes the Comparison

Conventional economic discussions of advanced therapeutics often focus on upfront cost alone. That framing is incomplete. CRISPR²™ changes the comparison by shifting intervention from a repeated, instability-prone model to a readiness-gated model that concentrates cost within defined windows of higher biological efficiency. In other words, the economic advantage of CRISPR²™ does not come from making advanced therapy cheap. It comes from making expensive intervention more efficient, better timed, and less wasteful.

This distinction reflects a broader shift in health economics from volume-based care to value-based and outcome-aligned intervention strategies, where timing, targeting, and durability play a central role in determining cost-effectiveness (Porter, 2010; Neumann et al., 2018). In autoimmune disease, where variability and relapse are primary cost drivers, aligning intervention with system readiness represents a structural mechanism for reducing long-term economic burden. This is the core difference between the traditional autoimmune model and the CYNAERA model.

Traditional vs CRISPR²™ Cost Logic in Autoimmune Disease

Dimension	Traditional Model	CYNAERA / CRISPR²™ Model
Intervention pattern	Repeated suppression and escalation	Time-bound, readiness-aligned intervention
Direct cost structure	Recurring annual burden	Concentrated deployment with reduced waste
Instability handling	Managed after flare or decline	Modeled before escalation through readiness and stabilization
Failure cost	Partial response, relapse, repeated cycling	Mistimed deployment, reduced through TRI and stabilization
Indirect burden	Accumulates across years and decades	Reduced through earlier stability and functional preservation
Economic frame	Cost per year	Cost per lifetime trajectory

This distinction matters because autoimmune disease is rarely a one-year problem. It is a decade-spanning cost architecture. When readiness, stabilization, and recovery are ignored, care remains trapped in high-variance management cycles. When those layers are integrated, a portion of that recurring waste becomes reducible.

Population-Scale Economic Impact

Using the annual burden already modeled in the CRISPR²™ framework, the combined cost of direct and indirect autoimmune burden falls within:

Combined annual burden: $35,000–$120,000 per patient per year

Applying partial efficiency and recovery gains across a corrected autoimmune population base produces substantial system-level value. Even conservative assumptions generate large savings.

Illustrative Annual Economic Value from Partial Improvement

Population Basis	Annual Economic Value
Diagnosed floor population	Tens of billions annually
Corrected autoimmune burden	Hundreds of billions annually
Higher corrected range + stronger efficiency gains	Potentially approaches trillion-scale long-horizon value

These estimates do not assume full remission for all patients. They reflect partial efficiency gains, reduced instability-driven cost, and improved functional recovery across a broader autoimmune population base.

Lifecycle Cost and Accumulation

A deeper limitation of standard cost models is that they assume autoimmune burden begins at diagnosis. In reality, burden often begins years earlier. As established through Stage Zero™, patients frequently experience prolonged periods of instability before formal recognition, including fatigue, inflammatory symptoms, exercise intolerance, fluctuating function, and reduced resilience. These early manifestations are often excluded from economic models even when they shape educational, developmental, and occupational outcomes for years. This is why autoimmune disease is not best understood as a midlife treatment cost. It is better understood as a lifetime accumulation problem.

System-Level Interpretation

The core issue is structural.

In current models:

• instability is treated after escalation

• cost is distributed across repeated management cycles

• variability is interpreted as therapeutic difficulty

• advanced intervention is judged primarily by price

In CYNAERA’s model:

• instability becomes measurable

• timing becomes actionable

• inefficiency becomes reducible

• advanced intervention is judged by lifetime trajectory impact

CRISPR²™ functions as an intervention-efficiency layer within remission-oriented care. By aligning deployment with readiness, stabilization, and recovery, it improves both clinical outcomes and economic efficiency without requiring unrealistic assumptions about perfect response.

Key Economic Implication

The value of remission-oriented intervention in autoimmune disease is not defined solely by the cost of advanced therapy. It is defined by its ability to:

• reduce repeated misaligned care cycles

• lower instability-driven direct cost

• improve workforce and functional recovery

• alter lifetime trajectory rather than yearly burden

• scale across a corrected autoimmune population base reflecting true system burden

Within this framework, CRISPR²™ is not only a therapeutic deployment model. It is economic infrastructure for managing chronic disease more efficiently under conditions of biological variability.

10. Hidden Cost Drivers and the Role of Personalization in Signal Detection

The economic models outlined in Section 8 capture measurable burden across direct care, workforce loss, and modeled efficiency gains. Even so, they still represent an undercount. A substantial portion of autoimmune disease cost remains structurally invisible because it accumulates before diagnosis, outside formal care pathways, and within systems that misinterpret or suppress early clinical signal. This gap is not incidental. It is built into the way disease is recognized, recorded, and valued. It represents a structural limitation in signal detection itself, where systems are optimized to capture visible disease rather than emerging instability.

One of the clearest sources of hidden burden is the pre-diagnostic phase of disease. In conventional models, economic burden begins at diagnosis. In practice, autoimmune disease often develops over years of unrecognized instability. Patients may experience persistent fatigue, joint instability, inflammatory discomfort, exercise intolerance, temperature sensitivity, and fluctuating functional capacity long before they meet formal criteria for diagnosis (Ramos-Casals et al., 2012; Castori et al., 2017; Mitchell et al., 2024). Within the Stage Zero™ framework, this period does not represent absence of disease, but structured, clinically meaningful dysfunction that has not yet been translated into a recognized category. Although these early manifestations are rarely captured in claims data or standard utilization models, they produce real cost through reduced activity, disrupted schooling, delayed workforce entry, impaired productivity, and the gradual accumulation of burden across development and early adulthood.

A second layer of hidden cost emerges through capacity masking. Many individuals adapt to chronic symptoms by increasing effort, modifying behavior, reducing activity privately, or suppressing visible signs of dysfunction in order to meet expectations. The result is that observed performance often exceeds true physiological capacity. In economic terms, this creates a major distortion. Patients may appear functional enough to avoid recognition while still paying a high internal cost in energy, pain, recovery time, and long-term destabilization. Similar dynamics have been described in chronic fatigue and pain populations, where patients continue functioning only by absorbing increasing physiological strain (Jason et al., 2015; Nijhof et al., 2016). Capacity masking does not reduce burden. It delays when systems are forced to count it, often making the eventual cost higher.

Closely related to this is the suppression of clinical signal at the patient level. Individuals frequently interpret early symptoms as normal variation, poor fitness, family traits, temperament, or personal weakness rather than as indications of underlying disease. When those signals are never recognized as medically relevant, they never enter the chart, never shape the history, and never inform testing. This contributes directly to delayed diagnosis and incomplete clinical data, reinforcing structural gaps in both care and economic measurement (Singh et al., 2019). The system then appears to confirm its own assumptions: what was not recorded is treated as if it never existed.

Fluctuation introduces an additional distortion. Autoimmune disease often follows a relapsing-remitting pattern, with symptoms that shift in intensity over time. In standard models, this variability is frequently interpreted as inconsistency rather than biological instability. Patients may be described as exaggerating, unreliable, or noncompliant when they are actually reporting a system that does not behave in a linear or static way (Komaroff and Bateman, 2021; Nalbandian et al., 2021). Within the CYNAERA framework, this is precisely the type of pattern SymCas™ is designed to capture, translating recurrence, sequencing, and delayed symptom response into structured evidence of instability rather than dismissible variability. This credibility gap has direct economic consequences. Delayed or denied care leads to more severe disease at presentation, greater reliance on high-cost interventions, and longer periods of unmanaged instability. In other words, disbelief is not just a social harm. It is a cost driver.

At the center of these failures is a mismatch in how signal is interpreted. Standard models evaluate symptoms according to absolute severity relative to population norms. However, autoimmune disease is often more accurately recognized through deviation from an individual baseline than through extreme values at a single point in time. A symptom that appears mild in a generalized framework may represent a major physiologic shift for a particular patient. This is why baseline-dependent interpretation matters so much.

Component	Standard Model	Personalized Model
Baseline	Ignored or assumed normal	Primary reference point
Event	Evaluated in isolation	Evaluated relative to individual baseline
Response	Compared to population norms	Compared to personal trajectory
Signal Detection	Based on absolute severity	Based on deviation and pattern
Outcome	Frequently dismissed	More likely to trigger investigation

When signal is interpreted in personalized rather than generalized terms, early instability becomes more visible and more actionable. That change has implications not only for diagnosis, but for timing, intervention strategy, and long-term cost. Real-world patient and caregiver management repeatedly demonstrates that understanding an individual baseline is often the most reliable method for detecting instability and guiding intervention. Within CYNAERA’s applied frameworks, baseline-aware signal detection is treated as foundational to flare identification, stabilization, and recovery planning.

The emotional and psychological burden associated with delayed recognition also functions as an economic driver, even though it is rarely modeled as one. Patients with prolonged diagnostic delay frequently experience stigma, disbelief, and repeated invalidation. Early symptoms may be reframed as personality problems, behavioral weakness, exaggeration, or emotional instability, leading over time to internalized shame and reduced willingness to seek care (Åsbring and Närvänen, 2002; Woldhuis et al., 2024). This has measurable downstream effects. Patients who delay care because they have learned not to trust their own bodies often present later with more advanced disease, require more intensive interventions, and experience more severe long-term impairment. In that sense, emotional burden is not separate from economic burden. It helps produce it.

This is where personalization becomes more than a clinical preference. Within the CRISPR Remission™ framework, personalization functions as a cost-correction mechanism. By anchoring interpretation to individual baseline and longitudinal pattern rather than static thresholds alone, early instability can be identified before it progresses into higher-cost disease states. This is strengthened further when baseline-aware interpretation is paired with SymCas™, which captures temporal symptom structure, and VitalGuard™, which models environmental pressure as a modifier of system stability rather than a background variable. When integrated with TRI and CRISPR²™, personalization helps ensure that intervention is not only biologically relevant, but timed in a way that reduces waste, improves readiness alignment, and lowers the probability of escalation into more severe and expensive forms of disease.

The hidden cost of autoimmune disease therefore follows a consistent logic. Early instability is present but unrecognized. Signal is suppressed, distorted, or dismissed. Intervention is delayed. Disease progresses into higher-cost states that appear more expensive because systems only begin counting them once they are obvious. In conventional models, cost begins at diagnosis, variability is treated as inconsistency, early symptoms are discounted, and emotional burden is excluded from economic analysis.

In CYNAERA’s model, cost begins at first meaningful instability, variability is structured and measurable, early signal is actionable, and emotional and behavioral responses are recognized as part of the broader system dynamics. The total cost of autoimmune disease is not limited to what is treated. It includes what is endured, adapted to, suppressed, and misinterpreted. Correcting this gap requires more than improved therapies alone. It requires improved detection, interpretation, and timing. Personalization, in this context, is not an optional enhancement layered onto care after the fact. It is a necessary condition for reducing hidden cost and aligning intervention with the way disease actually behaves.

11. Conclusion: CRISPR Remission™ and State-Dependent Gene Editing in Autoimmune Disease

Autoimmune disease has historically been approached as a problem of immune overactivity requiring suppression. Although this model has produced meaningful clinical advances, it has not delivered durable remission for most patients. The limitation is not simply therapeutic. It is structural. Current approaches continue to treat dynamic, multi-system disease as though it were stable, label-bound, and temporally static, even when the underlying biology behaves very differently.

This paper argues that achieving remission requires a different framework. Within the CRISPR Remission™ architecture, autoimmune disease is understood not as a fixed diagnosis alone, but as a system-level condition shaped by interacting biological, environmental, and temporal variables. Disease expression changes according to trigger history, dominant mechanisms, system state, recovery conditions, and external exposures. In that context, intervention cannot be defined by molecular relevance alone. It must also be aligned with readiness.

The integration of pattern-based stratification, multi-layer system classification, and the Target Readiness Index™ (TRI) provides the structure required for that shift. Pattern recognition identifies coherent disease trajectories across time, including temporal dynamics captured through systems such as SymCas™, which translate fluctuation into structured signal. Stratification organizes those trajectories into actionable models of system behavior. TRI then evaluates whether specific targets are actually deployable within a given system state, incorporating not only biological relevance but environmental pressure as quantified through systems such as VitalGuard™, as well as the need for pre-intervention stabilization through the STAIR Stable Method™. CRISPR²™ operationalizes this logic through readiness-based deployment, stabilization, and personalized recovery, transforming intervention from a static event into a coordinated system process.

This framework also helps explain why autoimmune and related immune-volatile conditions so often produce delayed diagnosis, inconsistent treatment response, and variable trial outcomes. These are not isolated failures. They reflect a broader mismatch between how disease behaves and how medicine continues to model it. When systems ignore timing sensitivity, environmental load, physiologic volatility, and recovery context, even promising interventions may appear inconsistent or fail to produce durable benefit. In that sense, the problem is not only which therapies are chosen, but whether they are deployed under conditions capable of supporting success.

Autoimmune disease serves as both a proving ground and a bridge within this model. It is a domain in which immune-reset strategies have already demonstrated enough clinical feasibility to justify serious translational investment, yet it also connects directly to a broader class of immune-volatile conditions, including Long COVID, ME/CFS, and dysautonomia, where similar system dynamics are present but less formally integrated into care. That is part of what makes autoimmune disease so strategically important. It is not only a therapeutic target. It is a domain through which a more general model of remission-capable medicine can be articulated.

This broader application is not theoretical. It is already being operationalized through initiatives such as The Eve Research Project, which is designed to capture longitudinal, real-world data on system instability, environmental exposure, and recovery dynamics in underrepresented populations. By generating structured data across time, The Eve Research Project provides a critical foundation for refining stratification, improving TRI scoring, and enabling more precise, state-dependent intervention across immune-volatile conditions.

The implications extend beyond gene editing itself. A target does not fail because it is biologically irrelevant. It may fail because it is deployed in the wrong system state. Recognizing that distinction changes the central task of intervention design. The question is no longer only what to target, but when, under what conditions, and within what degree of system readiness that target becomes truly actionable. This is the shift from intervention as a molecular event to intervention as a systems decision.

CRISPR Remission™ and CRISPR²™ represent one implementation of that broader shift. By linking pattern recognition, stratification, environmental modeling, readiness scoring, stabilization, and deployment into a unified architecture, they offer a framework for translating emerging therapeutic capabilities into durable clinical outcomes. If remission is to become a scalable and reliable outcome across autoimmune and related immune-volatile conditions, the field will need to move beyond static models of disease and adopt system-aware frameworks that reflect how these conditions actually behave across time, stress, recovery, and exposure. Autoimmune disease is not a moment of diagnosis. It is a lifetime of accumulation.

FAQ: CRISPR Remission™ in Autoimmune Disease

What is CRISPR Remission™ in autoimmune disease? 

CRISPR Remission™ is a state-dependent framework for achieving durable remission in autoimmune and immune-volatile conditions. Instead of focusing only on gene targets, it incorporates system stability, timing, and environmental context to determine when intervention is most likely to succeed. The goal is not partial suppression of symptoms, but long-term stabilization and potential remission.

What is CRISPR²™ and how is it different from standard CRISPR therapy? 

CRISPR²™ (CRISPR Readiness Index, Stabilization, and Personalized Recovery) is an advanced deployment model for gene editing. Traditional CRISPR approaches focus on what to edit. CRISPR²™ focuses on when and under what conditions to deploy that edit. By aligning intervention with system readiness using TRI, it improves safety, timing, and durability of outcomes.

Can CRISPR be used to treat autoimmune diseases? 

Emerging research, including CAR-T immune reset studies in lupus and related conditions, suggests that immune-targeted therapies can produce durable remission in autoimmune disease (Mackensen et al., 2022; Schett et al., 2023). CRISPR-based approaches are being explored as a next step, particularly when combined with system-level frameworks like CRISPR Remission™ that account for timing, stability, and patient-specific factors.

Why does timing matter in CRISPR or gene therapy for autoimmune disease? 

Autoimmune disease is not biologically static. Immune activity, inflammation, and system stability fluctuate over time. Intervening during periods of instability can reduce effectiveness or durability. CRISPR²™ addresses this by identifying optimal intervention windows using the Target Readiness Index™ (TRI), increasing the likelihood of long-term success.

What is the Target Readiness Index™ (TRI)? 

TRI is a scoring and decision framework that evaluates whether a therapeutic target is deployable within a given system state. It considers biological stability, environmental exposure, phenotype clarity, and system interaction complexity. Instead of treating all patients with the same diagnosis equally, TRI determines when intervention is most likely to work.

Is CRISPR gene therapy too expensive for autoimmune disease? 

CRISPR and advanced therapies are often described as expensive because of their upfront cost. However, this comparison is incomplete. Chronic autoimmune care can cost $35,000 to $120,000 per year over decades, leading to lifetime costs that can exceed $1M–$3M. CRISPR²™ reframes cost by concentrating intervention into a time-bound event that reduces long-term instability, making it potentially more efficient over a lifetime.

How does CRISPR²™ reduce healthcare costs if the therapy itself is expensive? 

CRISPR²™ reduces cost by improving deployment efficiency. By aligning treatment with system readiness, it lowers the risk of failed or mistimed interventions, reduces relapse cycles, and decreases long-term reliance on continuous therapies. The economic advantage comes from reducing instability-driven cost, not lowering the price of the procedure itself.

What role do environmental factors play in autoimmune disease treatment? 

Environmental factors such as air pollution, mold exposure, temperature shifts, and infectious triggers influence immune activity and disease stability. These factors can affect treatment outcomes by altering system readiness. Within CYNAERA’s framework, environmental inputs are treated as part of the system state, not external noise, allowing for more accurate timing and better intervention outcomes.

Why are autoimmune diseases often diagnosed late? 

Autoimmune diseases are frequently delayed in diagnosis because early symptoms are subtle, fluctuate, or do not meet strict clinical thresholds. Patients may also adapt to symptoms or have them dismissed as stress, personality traits, or minor issues. This leads to years of unrecognized disease, often referred to as Stage Zero™, where cost and damage accumulate before diagnosis.

What is Stage Zero™ in autoimmune disease? 

Stage Zero™ refers to the pre-diagnostic phase where patients experience real but unclassified dysfunction. Symptoms such as fatigue, instability, or inflammation may be present for years but are not formally recognized as disease. This phase carries significant hidden cost and plays a major role in long-term outcomes.

Why does personalization matter in autoimmune disease treatment? 

Autoimmune disease often presents as deviation from an individual’s baseline rather than extreme symptoms at a single point in time. Personalized frameworks track changes relative to that baseline, allowing earlier detection, better timing of intervention, and reduced long-term cost. Within CRISPR Remission™, personalization is essential for aligning treatment with system behavior.

Can autoimmune disease go into remission? 

Yes, remission is increasingly recognized as achievable in certain autoimmune conditions, particularly with immune-reset therapies such as CAR-T (Mackensen et al., 2022). The CRISPR Remission™ framework expands this concept by integrating timing, stability, and system-level modeling to increase the likelihood and durability of remission across a broader set of conditions.

CYNAERA Framework Papers

This paper draws on a defined subset of CYNAERA Institute white papers that establish the methodological and analytical foundations of CYNAERA’s frameworks. These publications provide deeper context on prevalence reconstruction, remission, combination therapies and biomarker approaches. Our Long COVID,  ME/CFS, Lyme and CRISPR Remission Libraries are also in depth resources.

• Target Readiness Index™ (TRI): CRISPR Target for IACCs

• Corrected National Prevalence Estimates for (IACCs)

• Personalized CRISPR Remission™ for Long COVID

• Personalized CRISPR Remission™ for Lyme

• Corrected National Prevalence Estimates for IACCs

• A Nobel-Scale Advance: AI-Powered CRISPR Platform for IACCs

• CYNAERA’s VitalGuard™ Environmental Flare Risk Engine

• SymCas™: Symptom Modeling Flare Prediction in IACCs

• Autoimmune Conditions Symptoms & Prevalence

Author’s Note:

All insights, frameworks, and recommendations in this written material reflect the author's independent analysis and synthesis. References to researchers, clinicians, and advocacy organizations acknowledge their contributions to the field but do not imply endorsement of the specific frameworks, conclusions, or policy models proposed herein. This information is not medical guidance.

Patent-Pending Systems

Bioadaptive Systems Therapeutics™ (BST) and affiliated CYNAERA frameworks are protected under U.S. Provisional Patent Application No. 63/909,951. CYNAERA is built as modular intelligence infrastructure designed for licensing, integration, and strategic deployment across health, research, public sector, and enterprise environments.

Licensing and Integration

CYNAERA supports licensing of individual modules, bundled systems, and broader architecture layers. Current applications include research modernization, trial stabilization, diagnostic innovation, environmental forecasting, and population level modeling for complex chronic conditions. Basic licensing is available through CYNAERA Market, with additional pathways for pilot programs, institutional partnerships, and enterprise integration.

About the Author 

Cynthia Adinig is the founder of CYNAERA, a modular intelligence infrastructure company that transforms fragmented real world data into predictive insight across healthcare, climate, and public sector risk environments. Her work sits at the intersection of AI infrastructure, federal policy, and complex health system modeling, with a focus on helping institutions detect hidden costs, anticipate service demand, and strengthen planning in high uncertainty environments.

Cynthia has contributed to federal health and data modernization efforts spanning HHS, NIH, CDC, FDA, AHRQ, and NASEM, and has worked with congressional offices including Senator Tim Kaine, Senator Ed Markey,  Representative Don Beyer, and Representative Jack Bergman on legislative initiatives related to chronic illness surveillance, healthcare access, and data infrastructure. In 2025, she was appointed to advise the U.S. Department of Health and Human Services and has testified before Congress on healthcare data gaps and system level risk.

She is a PCORI Merit Reviewer, currently advises Selin Lab at UMass Chan, and has co-authored research  with Harlan Krumholz, MD, Akiko Iwasaki, PhD, and David Putrino, PhD, including through Yale’s LISTEN Study. She also advised Amy Proal, PhD’s research group at Mount Sinai through its CoRE advisory board and has worked with Dr. Peter Rowe of Johns Hopkins on national education and outreach focused on post-viral and autonomic illness. Her CRISPR Remission™ abstract was presented at CRISPRMED26 and she has authored a Milken Institute essay on artificial intelligence and healthcare.

Cynthia has been covered by outlets including TIME, Bloomberg, Fortune, and USA Today for her policy, advocacy, and public health work. Her perspective on complex chronic conditions is also informed by lived experience, which sharpened her commitment to reforming how chronic illness is understood, studied, and treated. She also advocates for domestic violence prevention and patient safety, bringing a trauma informed lens to her research, systems design, and policy work. Based in Northern Virginia, she brings more than a decade of experience in strategy, narrative design, and systems thinking to the development of cross sector intelligence infrastructure designed to reduce uncertainty, improve resilience, and support institutional decision making at scale.

References

1. Ananthakrishnan, A.N., 2015. Environmental risk factors for inflammatory bowel disease. Gastroenterology & Hepatology, 11(6), pp. 395–400.

2. Ashley, E.A., 2016. Towards precision medicine. Nature Reviews Genetics, 17(9), pp. 507–522.

3. Baxter, L.K., Crooks, J., Sarnat, S.E. and Sarnat, J.A., 2021. Influence of climate and air pollution on respiratory and cardiovascular disease. Current Environmental Health Reports, 8(2), pp. 100–110.

4. Bernatsky, S., Smargiassi, A., Barnabe, C., et al., 2011. Fine particulate air pollution and systemic autoimmune rheumatic disease. Environmental Health Perspectives, 119(5), pp. 708–713.

5. Birnbaum, H., Pike, C., Kaufman, R., et al., 2010. Societal cost of rheumatoid arthritis patients in the US. Current Medical Research and Opinion, 26(1), pp. 77–90.

6. Bourdrel, T., Bind, M.A., Béjot, Y., Morel, O. and Argacha, J.F., 2021. Cardiovascular effects of air pollution. Archives of Cardiovascular Diseases, 114(11), pp. 733–745.

7. Brewer, J.H., Thrasher, J.D., Straus, D.C., Madison, R.A. and Hooper, D., 2013. Detection of mycotoxins in patients with chronic fatigue syndrome. Toxins, 5(4), pp. 605–617.

8. Burek, C.L. and Talor, M.V., 2009. Environmental triggers of autoimmune thyroid disease. Autoimmunity, 42(4), pp. 277–283.

9. Castori, M., Tinkle, B., Levy, H., Grahame, R., Malfait, F. and Hakim, A., 2017. A framework for the classification of joint hypermobility and related conditions. American Journal of Medical Genetics Part C, 175(1), pp. 148–157.

10. Collins, J.J., Baase, C.M., Sharda, C.E., et al., 2005. The assessment of chronic health conditions on work performance. Journal of Occupational and Environmental Medicine, 47(6), pp. 547–557.

11. Compston, A. and Coles, A., 2008. Multiple sclerosis. The Lancet, 372(9648), pp. 1502–1517.

12. Cross, M., Smith, E., Hoy, D., et al., 2014. The global burden of rheumatoid arthritis. Annals of the Rheumatic Diseases, 73(7), pp. 1316–1322.

13. Davidson, A. and Diamond, B., 2001. Autoimmune diseases. New England Journal of Medicine, 345(5), pp. 340–350.

14. D’Amato, G., Cecchi, L., D’Amato, M. and Liccardi, G., 2015. Urban air pollution and climate change as environmental risk factors of respiratory allergy. Journal of Investigational Allergology and Clinical Immunology, 25(5), pp. 307–312.

15. Davis, H.E., McCorkell, L., Vogel, J.M. and Topol, E.J., 2023. Long COVID: major findings and recommendations. Nature Reviews Microbiology, 21(3), pp. 133–146.

16. Doria, A., Gatto, M., Zen, M., Iaccarino, L. and Punzi, L., 2005. Optimizing outcome in SLE. Autoimmunity Reviews, 4(8), pp. 464–470.

17. Eaton, W.W., Rose, N.R., Kalaydjian, A., Pedersen, M.G. and Mortensen, P.B., 2020. Epidemiology of autoimmune diseases. American Journal of Epidemiology, 189(9), pp. 869–879.

18. Firestein, G.S. and McInnes, I.B., 2017. Immunopathogenesis of rheumatoid arthritis. Immunity, 46(2), pp. 183–196.

19. Georgiadis, C., Preece, R., Nickolay, L., et al., 2022. CRISPR-Cas9 gene editing for immune disorders. Nature Reviews Drug Discovery, 21(6), pp. 415–435.

20. Gladman, D.D., Antoni, C., Mease, P., Clegg, D.O. and Nash, P., 2005. Psoriatic arthritis: epidemiology and clinical features. Annals of the Rheumatic Diseases, 64(Suppl 2), pp. ii14–ii17.

21. Goetzel, R.Z., Long, S.R., Ozminkowski, R.J., et al., 2004. Health, absence, disability, and presenteeism cost estimates. Journal of Occupational and Environmental Medicine, 46(4), pp. 398–412.

22. Hayter, S.M. and Cook, M.C., 2012. Updated assessment of the prevalence of autoimmune disease. Autoimmunity Reviews, 11(10), pp. 754–765.

23. Hood, L. and Flores, M., 2012. A personal view on systems medicine. Nature Biotechnology, 30(6), pp. 579–582.

24. Ioannidis, J.P.A., 2005. Why most published research findings are false. PLoS Medicine, 2(8), e124.

25. Jacobson, D.L., Gange, S.J., Rose, N.R. and Graham, N.M.H., 1997. Epidemiology and estimated population burden of autoimmune diseases. Clinical Immunology and Immunopathology, 84(3), pp. 223–243.

26. June, C.H., O’Connor, R.S., Kawalekar, O.U., Ghassemi, S. and Milone, M.C., 2018. CAR T cell immunotherapy for human cancer. Science, 359(6382), pp. 1361–1365.

27. Kawatkar, A.A., Jacobsen, S.J., Levy, G.D., et al., 2012. Direct medical costs of rheumatoid arthritis. Journal of Rheumatology, 39(6), pp. 1120–1126.

28. Kent, D.M., Rothwell, P.M., Ioannidis, J.P.A., Altman, D.G. and Hayward, R.A., 2010. Assessing heterogeneity of treatment effects. BMJ, 340, c869.

29. Komaroff, A.L. and Bateman, L., 2021. Will COVID-19 lead to ME/CFS? Frontiers in Medicine, 7, 606824.

30. Landrigan, P.J., Fuller, R., Acosta, N.J.R., et al., 2018. The Lancet Commission on pollution and health. The Lancet, 391(10119), pp. 462–512.

31. Lerner, D., Reed, J.I., Massarotti, E., et al., 2015. The impact of rheumatoid arthritis on work. Arthritis Care & Research, 67(5), pp. 673–682.

32. Michaud, K., Messer, J., Choi, H.K. and Wolfe, F., 2015. Direct medical costs and their predictors in rheumatoid arthritis. Arthritis & Rheumatology, 48(10), pp. 2750–2762.

33. Müller, F., Schett, G., et al., 2026. CD19 CAR-T cell therapy in autoimmune disease. Nature Medicine, [in press].

34. Nalbandian, A., Sehgal, K., Gupta, A., et al., 2021. Post-acute COVID-19 syndrome. Nature Medicine, 27(4), pp. 601–615.

35. Neumann, P.J., Cohen, J.T. and Weinstein, M.C., 2018. Updating cost-effectiveness. New England Journal of Medicine, 371(9), pp. 796–797.

36. Parks, C.G., D’Aloisio, A.A., Sandler, D.P. and Taylor, K.W., 2017. Air pollution and autoimmune disease. Environmental Health Perspectives, 125(6), 066002.

37. Porter, M.E., 2010. What is value in health care? New England Journal of Medicine, 363(26), pp. 2477–2481.

38. Putrino, D., Tabacof, L., Tosto-Mancuso, J., et al., 2023. Post-acute sequelae of COVID-19. Nature Reviews Disease Primers, 9(1), 1–20.

39. Ramos-Casals, M., Brito-Zerón, P., Sisó-Almirall, A., Bosch, X. and Tzioufas, A.G., 2012. Primary Sjögren syndrome. BMJ, 344, e3821.

40. Rose, N.R. and Bona, C., 1993. Defining criteria for autoimmune diseases. Immunology Today, 14(9), pp. 426–430.

41. Schraufnagel, D.E., Balmes, J.R., De Matteis, S., et al., 2019. Health benefits of air pollution reduction. American Journal of Respiratory and Critical Care Medicine, 199(6), pp. 674–682.

42. Siegel, C.A., et al., 2023. Treatment patterns in autoimmune disease. Lancet Rheumatology, 5(3), pp. e123–e135.

43. Smolen, J.S., Aletaha, D. and McInnes, I.B., 2023. Rheumatoid arthritis. The Lancet, 401(10381), pp. 216–232.

44. Sokka, T., Kautiainen, H. and Pincus, T., 2008. Work disability in rheumatoid arthritis. Clinical and Experimental Rheumatology, 26(5 Suppl 51), pp. S71–S79.

45. Topol, E., 2019. Deep Medicine: How Artificial Intelligence Can Make Healthcare Human Again. New York: Basic Books.

46. Vu, T., et al., 2026. BCMA-directed mRNA CAR-T therapy in myasthenia gravis. Nature Medicine, [in press].